Highly active antiretroviral therapy (HAART) in adults with tuberculosis: Current status

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 3, 2005, Pages 248-257

  Flanigan, T P ^a   Carter, E J ^a   Kwara, Awewura ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

HAART; HIV; Interactions; TB

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; AMSACRINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFURTIDINE; ETHAMBUTOL; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ALOPECIA; BACTERIAL PNEUMONIA; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; DIRECTLY OBSERVED THERAPY; DOSE RESPONSE; EPIDEMIC; ERYTHEMA; EYE DISEASE; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; IMMUNOPATHOGENESIS; INSULIN RESISTANCE; JAUNDICE; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER TOXICITY; MALAISE; MORBIDITY; MORTALITY; MYOPATHY; NAUSEA; NEPHROLITHIASIS; OPTIC NERVE DISEASE; PAIN; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SKIN NODULE; STEATOSIS; SUPERINFECTION; TERATOGENICITY; THROMBOCYTOPENIA; TUBERCULOSIS; VOMITING;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; TUBERCULOSIS;

EID: 15344347209     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
2. Joint United Nations Programme on HIV/AIDS/World Health Organization. AIDS epidemic update: December 2003. Geneva, Switzerland: UNAIDS/WHO, 2003. www.unaids.org/wad/2003/epiupdate2003_en. Accessed March 2004.
3. Daley C L, Small P M, Schecter G F, et al. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency virus. An analysis using restriction fragment-length polymorphism. N Engl J Med 1992; 326: 231-235.
4. Selwyn P A, Hartel D, Lewis V A, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545-550.
5. Wolday D, Hailu B, Girma M, Hailu E, Sanders E, Fontanet A L. Low CD4+ T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV-positive Ethiopians. Int J Tuberc Lung Dis 2003; 7: 110-116.
6. Morris L, Martin D J, Bredell H, et al. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis 2003; 187: 1967-1971.
7. + T cells during M. tuberculosis infection. J Immunol 2001; 167: 6991-7000.
8. + T cells mediate IFN-γ-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol 2003; 171: 4689-4699.
9. Goletti D, Weissman D, Jackson R W, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996; 157: 1271-1278.
10. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003; 188: 1146-1155.
11. Whalen C, Horsburgh C R, Horn D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151: 129-135.
12. Whalen C C, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14: 1219-1228.
13. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 2001; 5: 225-232.
14. Leroy V, Salmi L R, Dupon M, et al. Progression of human immunodeficiency virus infection in patients with tuberculosis disease: a cohort study in Bordeaux, France, 1988-1994. Am J Epidemiol 1997; 145: 293-300.
15. Mukadi Y D, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2000; 15: 143-152.
16. Murray J, Sonnenberg P, Shearer S C, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159: 733-740.
17. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6-month) mortality. Am Rev Respir Dis 1992; 146: 849-854.
18. Churchyard G J, Kleinschmidt I, Corbett E L, Murray J, Smit J, De Cock K M. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 705-712.
19. De Cock K M, Chaisson R E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999; 3: 457-465.
20. Martin D J, Sim JGM, Sole G J, et al. CD4+ lymphocyte count in African patients co-infected with HIV and tuberculosis. J Acquir Immune Def Syndr Hum Retrovirol 1995; 8: 386-391.
21. Lawn S D, Shattock R J, Acheampong J W, et al. Sustained plasma TNF-á and HIV-I load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans. AIDS 1999; 13: 2231-2237.
22. Williams B G, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301: 1535-1537.
23. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence on tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
24. Santoro-Lopes G, Felix de Pinho A M, Harrison L H, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 543-546.
25. García de Olalla P, Martínez-González M A, Caylà J A, et al. Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients. Int J Tuberc Lung Dis 2002; 6: 1051-1057.
26. Dean G L, Edwards S G, Ives N J, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active anti-retroviral therapy. AIDS 2002; 16: 75-83.
27. Burman W J, Jones B E. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001; 164: 7-12.
28. American Thoracic Society Documents. American Thoracic Society/Centers of Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
29. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. 2003 Revision. Geneva, Switzerland: WHO, 2004. www. who.int/3by5/publications/en/ arv_eng.pdf. Accessed March 2004.
30. Kwara A, Carter E J, Rich J D, Flanigan T P. Development of opportunistic infections after diagnosis of active tuberculosis in HIV-infected patients. AIDS Patient Care STDs 2004; 18: 341-347.
31. Hung C-C, Chen M-Y, Hsiao C-F, Hsieh S-M, Sheng W-H, Chang S-C. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003; 17: 2615-2622.
32. Yeni P G, Hammer S M, Carpenter C J C, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the international AIDS Society-USA panel. JAMA 2002; 288: 222-235.
33. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: DHSS, National Institutes for Health, March 2004. aidsinfo.nih.gov/guidelines/ adult/AA_111003.pdf. Accessed 6 June 2004.
34. Monforte A D, Lepri A C, Rezza G, et al. Insights into the reasons for discontinuation of first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000; 14: 499-507.
35. Combalbert J, Fabre I, Dalet I, Derancourt J, Cano J P, Maurel P. Metabolism of cyclosporine A. IV. purification and identification of rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207.
36. Kolars J C, Schmiedlin-Ren P, Schuetz J D, Fang C, Watkins P B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-1878.
37. Kim R B, Fromm M F, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
38. Schuetz E G, Schinkel A H, Relling M V, Schuetz J D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci 1996; 93: 4001-4005.
39. Benedek I H, Joshi A, Fiske W D, et al. Pharmacokinetic interaction berween efavirenz and rifampin in healthy volunteers [abstract]. Geneva, Switzerland: 12th World AIDS Conference, June 28-July 3, 1998.
40. Lopéz-Cortés L F, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41: 681-690.
41. Ribera E, Pou L, Lopez R M, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. AIDS 2001; 28: 450-453.
42. Oliva J, Moreno S, Sanz J, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS 2003; 17: 637-638.
43. Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Atlanta, GA: CDC, 2004. www.cdc.gov/nchstp/tb/TB_HIV_Drugs/PDF/tbhiv.pdf. Accessed March 2004.
44. Pedral-Samapio D, Alves C, Netto E, et al. Efficacy of efavirenz 600 mg dose in the ARV therapy regimen for HIV patients receiving rifampicin in the treatment tuberculosis. Boston, MA: 10th Conference on Retroviruses and Opportunistic Infections, February 2003 [abstract 784] www.retroconference.org/ 2003/Abstract/Abstract.aspx?AbstractID = 1930. Accessed March 2004.
45. Dean G L, Back D J, de Ruiter A. Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS 1999; 13: 2489-2490.
46. Veldkamp A I, Hoetelmans R M W, Beijnen J H, Mulder J W, Meenhorst P L. Ritonovir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999; 29: 1586.
47. La Porte C J L, Colbers E P H, Bertz R, Koopmans P P, Hekster Y A, Burger D M. Pharmacokinetics (PK) of two adjusted dose regimens of lopinavir/ritonovir (LPV/r) in combination with rifampin (RIF) in healthy volunteers [abstract A-1823]. San Diego, CA: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2002. www. medadvocates.org/resources/conferences/ icaac/4ICAAC/E0202251BBLaPorte.pdf. Accessed 7 June 2004.
48. Desta Z, Soukhova N V, Flockhart D A. Inhibition of cytochrome P450 (CYP450) by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001; 45: 382-392.
49. 450 1A2, 2A6, 2C19, and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002; 57: 799-804.
50. Hung C-C, Lee H-C, Hsieh S-M, et al. Effectiveness of highly active antiretroviral therapy and antituberculous therapy combinations among HIV-infected patients with active tuberculosis. San Francisco, CA: 11th Conference on Retroviruses and Opportunistic Infections, February 2004. [abstract 763] www.retroconference.org/2004/cd/abstract/763.htm. Accessed 4 June 2004.
51. Tuberculosis Trials Consortium. Intermittent rifabutin and isoniazid with daily efavirenz-based antiretroviral therapy. San Francisco, CA: llth Conference on Retroviruses and Opportunistic Infections, February 2004. [abstract 761]. www.retroconference. org/2004/cd/abstract/761.htm. Accessed June 2004.
52. Okwera A, Whalen C, Byekwaso F, et al. Randomized trial of thiocetazone and rifampin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994; 344: 1323-1328.
53. Elliott A M, Halwindi B, Hayes, R J, et al. Impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in Zambia. Trans R Soc Trop Med Hyg 1995; 89: 78-82.
54. Korenromp E L, Scano F, Williams B G, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003; 37: 101-112
55. Gallicano K D, Sahai J, Shukla V K, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 1999; 48: 168-179.
56. Gulick R M, Ribaudo H J, Shikuma C M, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850-1861.
57. Gerstoft J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimens abacavir, stavudine and didanosine. AIDS 2003; 17: 2045-2052.
58. van Leeuwen R, Katlama C, Murphy R L, et al. A randomized trial to study first-line combination therapy with or without a prorease inhibitor in HIV-1-infected patients. AIDS 2003; 17: 987-999.
59. Narita M, Ashkin D, Hollender E S, Pitchenik A E. Paradoxical worsening of tuberculosis following antiretroviral therapy in-patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-161.
60. Navas E, Martín-Dávila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162: 97-99.
61. Wendel K A, Alwood K S, Gachuhi R, et al. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001; 120: 193-197.
62. Kumarasamy N, Chagaruru S, Mayer K H, et al. Incidence of immune reconstitution syndrome in HIV-TB co-infected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004; 37: 1574-1576.
63. Weis S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184.
64. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York-turning the tide. N Engl J Med 1995; 333: 229-233.
65. Zwarenstein M, Schoeman J H, Vundule C, Lombard C J, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998; 352: 1340-1343.
66. Walley J D, Khan M A, Newell J N, Khan M H. Effectiveness of the directly observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 2001; 357: 664-669.
67. Kamolratanakul P, Sawert H, Lertmaharit S, et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999; 93: 552-557.
68. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet 2000; 355: 1345-1350.
69. Lucas G M, Flexner C W, Moore R D. Directly administered antiretroviral therapy in treatment of HIV infection: benefit or burden? AIDS Patient Care STDs 2002; 16: 527-535.
70. Farmer P, Léandre F, Mukherjee J, Gupta R, Tarter L, Kim J Y. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ 2001; 79: 1145-1151.
71. Lurie M N, Carter E J, Cohen J, Flanigan T P. Directly observed therapy for HIV/tuberculosis co-infection. Lancet Infect Dis 2004; 4: 137-138.
72. Liechty C A, Bangsberg D R. Doubts about DOT: antiretroviral therapy for resource-poor countries. AIDS 2003; 17: 1383-1387.